PTP4A3 and neoplasm: For example, PRL3‐zumab, a first‐in‐class humanised mAb in phase 1 clinical trials, has been reported to promote the infiltration of B cells, NK cells and macrophages into the tumour microenvironment, leading to a ‘Kill‐and‐leak’ cascade [12, 13].